---
title: "DAJIAWEIKANG's subsidiary has obtained the drug registration certificate for Azithromycin dry suspension"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288238823.md"
description: "DAJIAWEIKANG announced that its wholly-owned subsidiary, DAJIAWEIKANG Biopharmaceutical Co., Ltd., recently obtained the \"Drug Registration Certificate\" for Azithromycin Dry Suspension issued by the National Medical Products Administration. This drug is suitable for the treatment of various mild to moderate infections caused by sensitive strains, including acute exacerbations of chronic bronchitis, community-acquired pneumonia, acute otitis media, sinusitis, pharyngitis/tonsillitis, and skin infections"
datetime: "2026-06-01T08:26:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288238823.md)
  - [en](https://longbridge.com/en/news/288238823.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288238823.md)
generator: "portal-rs"
---

# DAJIAWEIKANG's subsidiary has obtained the drug registration certificate for Azithromycin dry suspension

According to the Zhitong Finance APP, DAJIAWEIKANG (301126.SZ) announced that its wholly-owned subsidiary, DAJIAWEIKANG Biopharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for Azithromycin Dry Suspension approved and issued by the National Medical Products Administration.

The indications for Azithromycin Dry Suspension include the following: Azithromycin is a macrolide antibiotic suitable for the treatment of mild to moderate infections caused by specified microbial sensitive strains in the following specific conditions: 1. Acute exacerbation of bacterial infection in chronic bronchitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 2. Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae; 3. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 4. Acute bacterial sinusitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 5. Pharyngitis/tonsillitis caused by Streptococcus pyogenes; 6. Simple skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae; 7. Urethritis and cervicitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae; 8. Male genital ulcer disease (chancroid) caused by Haemophilus ducreyi. Due to the low number of women recruited in clinical trials, the efficacy of Azithromycin in treating female chancroid has not yet been determined

### Related Stocks

- [301126.CN](https://longbridge.com/en/quote/301126.CN.md)

## Related News & Research

- [MedicalRite Announces COVID-19 & Flu Combo Test for Better Health](https://longbridge.com/en/news/297204162.md)
- [HBIS Group, GLP China explore logistics, data center collaboration](https://longbridge.com/en/news/297165496.md)
- [Jinhui Shipping, Jinhui Holdings subsidiary, posts Q2 net profit of US$5.27 million](https://longbridge.com/en/news/297122309.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**